NeuropaceNPCE
NPCE
About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Employees: 195
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
600% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 5
340% more call options, than puts
Call options by funds: $22K | Put options by funds: $5K
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
45% more funds holding
Funds holding: 62 [Q4 2024] → 90 (+28) [Q1 2025]
26% more capital invested
Capital invested by funds: $234M [Q4 2024] → $294M (+$60.6M) [Q1 2025]
3.59% more ownership
Funds ownership: 69.91% [Q4 2024] → 73.5% (+3.59%) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
45%
upside
Avg. target
$17
54%
upside
High target
$18
63%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen | 63%upside $18 | Buy Initiated | 28 May 2025 |
JP Morgan Robbie Marcus | 45%upside $16 | Overweight Maintained | 14 May 2025 |
Cantor Fitzgerald Ross Osborn | 54%upside $17 | Overweight Reiterated | 14 May 2025 |
Financial journalist opinion
Based on 50 articles about NPCE published over the past 30 days
Neutral
Accesswire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Neutral
Accesswire
2 days ago
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
NEW YORK, NY / ACCESS Newswire / June 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against NeuroPace, Inc. (NPCE) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ: NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
3 days ago
Potential Securities Fraud: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE)
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against NeuroPace, Inc. (NPCE) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NASDAQ:NPCE). Investors who purchased NeuroPace securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NPCE.
Neutral
Accesswire
3 days ago
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Neutral
Accesswire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
4 days ago
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible violations of federal securities laws. NeuroPace issued a press release on May 27, 2025, "announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).
Charts implemented using Lightweight Charts™